BEDFORD, Ohio, Feb. 16 Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., a provider of select specialty injectables, is pleased to announce the addition of Indomethacin for Injection to its existing product line. This product is AP rated and is equivalent to Indocin® by Lundbeck, Inc. Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750 g when after 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly and pulmonary plethora on chest x-ray.
Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO)
Bedford Laboratories will supply Indomethacin for Injection USP as single dose vials containing indomethacin sodium, equivalent to 1 mg indomethacin. "We are very excited and pleased to announce the launch of this critical product. The release of this product to the market place is very timely, given that the innovator product is currently on long-term backorder (source: www.fda.gov). This is a great milestone for Bedford Laboratories and we are very proud to add this product to our growing portfolio," said David Gaugh, Vice President and General Manager, Bedford Laboratories.
Advertisement
Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.
About Bedford Laboratories
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products offering a broad range of multisource injectables across multiple therapeutic classes. Bedford Laboratories is one of the largest generic injectable pharmaceutical companies in the US.
Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc. For more information on Bedford Laboratories, visit www.bedfordlabs.com.
About Ben Venue Laboratories, Inc.
Ben Venue Laboratories, Inc. was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. Ben Venue has been under contract with the National Cancer Institute since 1967 to develop parenteral dosage forms for many anticancer agents. It has also manufactured various AIDS-specific drugs in conjunction with the NCI. Ben Venue employs more than 1,300 people. For more information on Ben Venue Laboratories and current career opportunities, visit www.benvenue.com.
Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies (Ingelheim, Germany). For more information, please visit http://us.boehringer-ingelheim.com.
Indocin® is a registered trademark of Lundbeck, Inc.
SOURCE Bedford Laboratories
